Stiripentol

Evidence Level: N/A

Predicted Indications: 0

Stiripentol

Pharmacist Assessment Report

Stiripentol: Known uses and market status in Australia

Summary

The TxGNN model has no candidate with a score of 0.99 or higher for Stiripentol, so there is currently no new predicted indication. The drug’s recorded uses are listed below.

Quick overview

Item	Content
New predicted indications	None (no model candidate scored 0.99 or higher)
Known uses recorded for this drug	4
Evidence level	Not applicable
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)

Known uses recorded for this drug

Approved (supported by a licence or label)

Indication	Source
juvenile myoclonic epilepsy	licence in another country

Indication	Approved category
none	none

Relations recorded in the knowledge graph (no approval found)

Indication
developmental and epileptic encephalopathy
dravet syndrome
early myoclonic encephalopathy

Australia Market Information

Licence	Product	Dosage form	Status
12088F	Diacomit	Powder for oral suspension 500 mg	Valid

Safety Considerations

Drug Interactions (100 interactions recorded; examples below):

Major: eliglustat.
Moderate: rabeprazole, omeprazole, cimetidine, clarithromycin, aprepitant, morphine, pioglitazone, saxagliptin, dronabinol, diphenoxylate, difenoxin, eluxadoline, palonosetron, and several corticosteroids (hydrocortisone, dexamethasone, betamethasone, triamcinolone, budesonide).

Warnings and contraindications are not available in the data compiled for this report. Please refer to the TGA-approved Product Information (PI) for these details.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.